However, only a few novel treatments were introduced, such as BRAF-related targeting therapies in low-grade gliomas, and preliminary studies of histone deacetylase (HDAC) inhibitors in paediatric high-grade gliomas [6], necessitating the development of new therapeutic strategies. The gene discussed is HDAC9; the disease is central nervous system cancer.